This interesting study linked germline testing and EHR/registry data from the UK NHS to characterize the risk of 2nd primary cancers for pts w/ pathogenic variants in BRCA1/BRCA2. 10-yr cumulative risk of contralateral BC was 16% in BRCA1+ and 12% in BRCA2+ https://ascopubs.org/doi/10.1200/JCO.24.01146